JP2009545756A - タンパク質凝集を予測し凝集阻害物質を設計する方法 - Google Patents
タンパク質凝集を予測し凝集阻害物質を設計する方法 Download PDFInfo
- Publication number
- JP2009545756A JP2009545756A JP2009523338A JP2009523338A JP2009545756A JP 2009545756 A JP2009545756 A JP 2009545756A JP 2009523338 A JP2009523338 A JP 2009523338A JP 2009523338 A JP2009523338 A JP 2009523338A JP 2009545756 A JP2009545756 A JP 2009545756A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- aggregation
- peptide
- peptide sequence
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 230000002776 aggregation Effects 0.000 title claims abstract description 85
- 238000004220 aggregation Methods 0.000 title claims abstract description 85
- 230000004845 protein aggregation Effects 0.000 title claims abstract description 29
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 160
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 145
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 145
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 238000012360 testing method Methods 0.000 claims abstract description 21
- 238000004590 computer program Methods 0.000 claims abstract description 5
- 235000018102 proteins Nutrition 0.000 claims description 121
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 18
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 150000008574 D-amino acids Chemical class 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108010067902 Peptide Library Proteins 0.000 claims description 8
- 230000033077 cellular process Effects 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 238000006384 oligomerization reaction Methods 0.000 claims description 5
- 108010071690 Prealbumin Proteins 0.000 claims description 4
- 102000009190 Transthyretin Human genes 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- 230000001594 aberrant effect Effects 0.000 claims description 3
- -1 crystallin Proteins 0.000 claims description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 102400000524 Fibrinogen alpha chain Human genes 0.000 claims description 2
- 101710137044 Fibrinogen alpha chain Proteins 0.000 claims description 2
- 108090001064 Gelsolin Proteins 0.000 claims description 2
- 102000004878 Gelsolin Human genes 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000011782 Keratins Human genes 0.000 claims description 2
- 108010076876 Keratins Proteins 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 108010057464 Prolactin Proteins 0.000 claims description 2
- 102000003946 Prolactin Human genes 0.000 claims description 2
- 102000008847 Serpin Human genes 0.000 claims description 2
- 108050000761 Serpin Proteins 0.000 claims description 2
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
- 108700006666 betaIG-H3 Proteins 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 108010054442 polyalanine Proteins 0.000 claims description 2
- 108010040003 polyglutamine Proteins 0.000 claims description 2
- 229920000155 polyglutamine Polymers 0.000 claims description 2
- 229940097325 prolactin Drugs 0.000 claims description 2
- 230000004952 protein activity Effects 0.000 claims description 2
- 239000003001 serine protease inhibitor Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 3
- 150000008575 L-amino acids Chemical class 0.000 claims 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims 1
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 1
- 108010012715 Superoxide dismutase Proteins 0.000 claims 1
- 230000004931 aggregating effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 17
- 230000003993 interaction Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000006933 amyloid-beta aggregation Effects 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 102100027812 Gamma-crystallin D Human genes 0.000 description 4
- 101710092801 Gamma-crystallin D Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 230000003942 amyloidogenic effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 101710190759 Serum amyloid A protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101710186621 Glycine cleavage system transcriptional repressor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 1
- 101710191666 Lactadherin Proteins 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- 102400001156 Medin Human genes 0.000 description 1
- 101800003015 Medin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 102000013069 gamma-Crystallins Human genes 0.000 description 1
- 108010079934 gamma-Crystallins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000003644 lens cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 102220024746 rs199473444 Human genes 0.000 description 1
- 102220139548 rs61735306 Human genes 0.000 description 1
- 102220184859 rs772223730 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007645 synaptic failure Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82155306P | 2006-08-04 | 2006-08-04 | |
| PCT/GB2007/002789 WO2008015384A1 (en) | 2006-08-04 | 2007-07-24 | Method for predicting protein aggregation and designing aggregation inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545756A true JP2009545756A (ja) | 2009-12-24 |
| JP2009545756A5 JP2009545756A5 (enExample) | 2010-09-09 |
Family
ID=38573441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523338A Pending JP2009545756A (ja) | 2006-08-04 | 2007-07-24 | タンパク質凝集を予測し凝集阻害物質を設計する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8290713B2 (enExample) |
| EP (1) | EP2047393A1 (enExample) |
| JP (1) | JP2009545756A (enExample) |
| KR (1) | KR20090047470A (enExample) |
| CN (1) | CN101501694B (enExample) |
| AU (1) | AU2007280282B2 (enExample) |
| CA (1) | CA2657847A1 (enExample) |
| EA (1) | EA016884B1 (enExample) |
| IL (1) | IL196551A (enExample) |
| SG (1) | SG173405A1 (enExample) |
| WO (1) | WO2008015384A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170094798A (ko) * | 2015-01-06 | 2017-08-21 | 노쓰 캐롤라이나 스테이트 유니버시티 | 이종 단백질 생성을 최적화하기 위한 리보좀 역학 모델링 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| GB2455102A (en) * | 2007-11-28 | 2009-06-03 | Cambridge Entpr Ltd | Protein Aggregation Prediction Systems |
| EP2278998A1 (en) | 2008-04-17 | 2011-02-02 | Declion Pharmaceuticals, Inc. | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
| CN110187119B (zh) * | 2008-10-31 | 2022-07-29 | 耶鲁大学 | 子痫前期检测和治疗的方法和组合物 |
| WO2011047442A1 (en) * | 2009-10-23 | 2011-04-28 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using same |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| FI20105629A0 (fi) * | 2010-06-03 | 2010-06-03 | Estaja Oy | Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US20120108904A1 (en) * | 2010-10-20 | 2012-05-03 | Yong Ma | Cleaner for endoscope |
| CN103772487B (zh) * | 2012-10-24 | 2015-11-25 | 国家纳米科学中心 | 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用 |
| US9618524B2 (en) * | 2014-03-26 | 2017-04-11 | Plaxgen Inc. | Method, composition, isolation and identification of a plaque particle and related biomarker |
| CN104502219B (zh) * | 2014-12-18 | 2017-09-29 | 江苏大学 | 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法 |
| GB201600176D0 (en) * | 2016-01-06 | 2016-02-17 | Cambridge Entpr Ltd | Method of identifying novel protein aggregation inhibitors based on chemical kinetics |
| BR112018014870A2 (pt) * | 2016-01-21 | 2018-12-11 | Protein Dynamic Solutions Llc | método e sistema para análise de dados espectrais |
| US10815271B2 (en) * | 2016-06-29 | 2020-10-27 | The Regents Of The University Of California | Structure-based peptide inhibitors of alpha-synuclein aggregation |
| CN106501550A (zh) * | 2016-12-09 | 2017-03-15 | 江苏大学 | 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法 |
| CN111653310B (zh) * | 2020-06-29 | 2023-06-20 | 北京大学深圳研究生院 | 含二硫键多肽的结构预测方法及装置 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004513873A (ja) * | 1999-11-05 | 2004-05-13 | アクソニックス，インコーポレイティド | アミロイド、アミロイド様沈着物またはそれらのβ−シートリッチな病理前駆体への異常タンパク質折り畳みに関係する疾患の治療における生体内使用に適するペプチド類似物および模倣物 |
| WO2005000288A2 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325817D0 (en) | 2003-11-05 | 2003-12-10 | Univ Cambridge Tech | Method and apparatus for assessing polypeptide aggregation |
-
2007
- 2007-07-24 KR KR1020097002794A patent/KR20090047470A/ko not_active Ceased
- 2007-07-24 CN CN2007800290322A patent/CN101501694B/zh not_active Expired - Fee Related
- 2007-07-24 EA EA200970180A patent/EA016884B1/ru not_active IP Right Cessation
- 2007-07-24 US US12/376,233 patent/US8290713B2/en not_active Expired - Fee Related
- 2007-07-24 SG SG2011052834A patent/SG173405A1/en unknown
- 2007-07-24 AU AU2007280282A patent/AU2007280282B2/en not_active Ceased
- 2007-07-24 JP JP2009523338A patent/JP2009545756A/ja active Pending
- 2007-07-24 WO PCT/GB2007/002789 patent/WO2008015384A1/en not_active Ceased
- 2007-07-24 EP EP07789035A patent/EP2047393A1/en not_active Withdrawn
- 2007-07-24 CA CA002657847A patent/CA2657847A1/en not_active Abandoned
-
2009
- 2009-01-15 IL IL196551A patent/IL196551A/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004513873A (ja) * | 1999-11-05 | 2004-05-13 | アクソニックス，インコーポレイティド | アミロイド、アミロイド様沈着物またはそれらのβ−シートリッチな病理前駆体への異常タンパク質折り畳みに関係する疾患の治療における生体内使用に適するペプチド類似物および模倣物 |
| WO2005000288A2 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
Non-Patent Citations (3)
| Title |
|---|
| JPN5009011081; ＤＥ ＧＲＯＯＴ ＮＡＴＡＬＩＡ ＳＡＮＣＨＥＺ: ＢＭＣ ＳＴＲＵＣＴＵＲＡＬ ＢＩＯＬＯＧＹ Ｖ５ Ｎ１８, 20050930, Ｐ１-１５, ＢＩＯＭＥＤ ＣＥＮＴＲＡＬ ＬＴＤ． * |
| JPN5009011082; ＰＡＷＡＲ Ａ Ｐ: ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＢＩＯＬＯＧＹ Ｖ３５０ Ｎ２, 20050708, Ｐ３７９-３９２ * |
| JPN6012062078; ＴＡＫＡＨＡＳＨＩ Ｔｓｕｙｏｓｈｉ ｅｔ ａｌ．: 'Ｐｅｐｔｉｄｅ ａｎｄ Ｐｒｏｔｅｉｎ Ｍｉｍｅｔｉｃｓ Ｉｎｈｉｂｉｔｉｎｇ Ａｍｙｌｏｉｄ beta-Ｐｅｐｔｉｄｅ Ａｇｇｒｅｇａｔｉｏｎ' Ａｃｃ． Ｃｈｅｍ． Ｒｅｓ． Ｖｏｌ．４１，Ｎｏ．１０, 200810, Ｐ．１３０９-１３１８ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170094798A (ko) * | 2015-01-06 | 2017-08-21 | 노쓰 캐롤라이나 스테이트 유니버시티 | 이종 단백질 생성을 최적화하기 위한 리보좀 역학 모델링 |
| KR102473180B1 (ko) | 2015-01-06 | 2022-12-01 | 노쓰 캐롤라이나 스테이트 유니버시티 | 이종 단백질 생성을 최적화하기 위한 리보좀 역학 모델링 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL196551A (en) | 2013-01-31 |
| SG173405A1 (en) | 2011-08-29 |
| EA016884B1 (ru) | 2012-08-30 |
| KR20090047470A (ko) | 2009-05-12 |
| EP2047393A1 (en) | 2009-04-15 |
| CN101501694A (zh) | 2009-08-05 |
| US8290713B2 (en) | 2012-10-16 |
| CA2657847A1 (en) | 2008-02-07 |
| WO2008015384A1 (en) | 2008-02-07 |
| HK1131239A1 (en) | 2010-01-15 |
| AU2007280282A1 (en) | 2008-02-07 |
| CN101501694B (zh) | 2011-11-30 |
| AU2007280282B2 (en) | 2012-02-02 |
| US20100160602A1 (en) | 2010-06-24 |
| IL196551A0 (en) | 2009-11-18 |
| WO2008015384A8 (en) | 2008-05-15 |
| EA200970180A1 (ru) | 2009-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009545756A (ja) | タンパク質凝集を予測し凝集阻害物質を設計する方法 | |
| Freddolino et al. | Force field bias in protein folding simulations | |
| Mo et al. | Conformational ensemble of hIAPP dimer: insight into the molecular mechanism by which a green tea extract inhibits hIAPP aggregation | |
| Yu et al. | Transient β-hairpin formation in α-synuclein monomer revealed by coarse-grained molecular dynamics simulation | |
| Charoenkwan et al. | iAMY-SCM: Improved prediction and analysis of amyloid proteins using a scoring card method with propensity scores of dipeptides | |
| Liu et al. | Disclosing the mechanism of spontaneous aggregation and template-induced misfolding of the key hexapeptide (PHF6) of tau protein based on molecular dynamics simulation | |
| Sommer et al. | Structure-guided isoform identification for the human transcriptome | |
| Saravanan et al. | On the conformational dynamics of β-amyloid forming peptides: A computational perspective | |
| Joseph et al. | Disease-associated mutations in CEP120 destabilize the protein and impair ciliogenesis | |
| Robinson et al. | Are AMBER force fields and implicit solvation models additive? A folding study with a balanced peptide test set | |
| Fatafta et al. | A brief history of amyloid aggregation simulations | |
| Linh et al. | Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study | |
| Pujols et al. | A3D 2.0 update for the prediction and optimization of protein solubility | |
| Rogne et al. | Atomic-level structure characterization of an ultrafast folding mini-protein denatured state | |
| Huang et al. | Unveiling medin folding and dimerization dynamics and conformations via atomistic discrete molecular dynamics simulations | |
| Black et al. | Evaluating calmodulin–protein interactions by rapid photoactivated cross-linking in live cells metabolically labeled with photo-methionine | |
| Djikic et al. | Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities | |
| Zganec et al. | Assembly of stefin B into polymorphic oligomers probed by discrete molecular dynamics | |
| Jakubek et al. | Polyglutamine solution-state structural propensity is repeat length dependent | |
| Puławski et al. | Multiscale modeling of protofilament structures: A case study on insulin amyloid aggregates | |
| HK1131239B (en) | Method for predicting protein aggregation and designing aggregation inhibitors | |
| Pantoja-Uceda et al. | The NMR structure and dynamics of the two-domain tick carboxypeptidase inhibitor reveal flexibility in its free form and stiffness upon binding to human carboxypeptidase B | |
| Bokor et al. | Wide-line NMR melting diagrams, their thermodynamic interpretation, and secondary structure predictions for A30P and E46K α-synuclein | |
| Hirschbeck et al. | Investigating a Novel Neurodegenerative Disease Toxic Mechanism Involving Lipid Binding Specificity of Amyloid Oligomers | |
| Javanmard et al. | In-silico structural analysis of Heterocephalus glaber amyloid beta: an anti-Alzheimer's peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100723 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100723 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130214 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130221 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130826 |